US QIDP Status Awarded to Meropenem Combo Med for Carbapenem-Resistant Bacteria Infections: Kitasato/Sumitomo

The Kitasato Institute and Sumitomo Pharma said on September 29 that they have scored Qualified Infectious Disease Product (QIDP) status and fast track designation from the US FDA for the fixed-dose combination of meropenem and KSP-1007 for the treatment of...read more